http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012102319-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-04 |
| filingDate | 2010-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012102319-A |
| titleOfInvention | NEW ANTIVIRAL COMPOUNDS SUITABLE FOR TREATMENT OR PREVENTION OF EPIDEMIC KERATO-CONJUNCTIVITIS |
| abstract | 1. The compound according to formula (I): where R is a methyl or ethyl group; R is R, R or R; “X” is O, S or NH; and “A” is Salkandiyl if R is R, and Salkandiyl if R is R or R, where X and R are bonded to different carbon atoms of said alkanediyl, and where said different carbon atoms are the most distant carbon atoms in said alkanediyl; R is selected from the group consisting of N (C1-6 alkyl) C (O) R, OC (O) R, C (O) N (C1-6 alkyl) R and C (O) OR, where R represents a linear carbon chain containing from 14 to 30 carbon atoms; wherein said carbon chain is saturated or contains one or more double and / or triple bonds; in addition, said carbon chain is unsubstituted or substituted by one or more C-C 1-6 alkyl groups; R 1 represents a substituent according to formula (II): wherein “D” is linked to “A”; “D” is selected from the group consisting of N (C 1-6 alkyl) C (O), OC (O), C (O) N (C1-6 alkyl) and C (O) O; the integer “m” is from 0 (zero) to 3; the integer “n” is from 1 to 15; the integer “p” is from 0 (zero) to 3; “E” is selected from the group consisting of N (C1-6 alkyl) C (O), OC (O), C (O) N (C1-6 alkyl) and C (O) O; R is selected from the group consisting of R as defined above and R, where R is substituent according to formula (III): wherein each independently is as defined above and attached to Salkandiil "E"; and R is selected from the group consisting of N (C1-6 alkyl) C (O) R, OC (0) R, C (O) N (C1-6 alkyl) R and C (O) OR, where R is a substituent according to formula (IV): wherein each R is independently is as defined above; as an acid in uncharged protonated form, pharmaceutical |
| priorityDate | 2009-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.